Pharmaceutical composition for treating and/or preventing cancer
According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity with a partial polypeptide of CAPRIN-1, wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30, and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence.
1. A method for treating a CAPRIN-1 expressing cancer and/or preventing the recurrence of a CAPRIN-1 expressing cancer, comprising administering to a subject an antibody or a fragment thereof which has immunological reactivity with a polypeptide that consists of the amino acid sequence of SEQ ID NO: 37, and has immunological reactivity with CAPRIN-1 polypeptide.
2. A method for treating a CAPRIN-1 expressing cancer and/or preventing the recurrence of a CAPRIN-1 expressing cancer, comprising administering to a subject a pharmaceutical combination comprising:
(i) an antibody or fragment thereof that has immunological reactivity with a polypeptide that consists of the amino acid sequence of SEQ ID NO:37, and that has immunological reactivity with CAPRIN-1 polypeptide; and
(ii) an antitumor agent.
3. A method for treating a CAPRIN-1 expressing cancer and/or preventing the recurrence of a CAPRIN-1 expressing cancer, comprising administering to a subject a pharmaceutical composition comprising an antibody or fragment thereof that has immunological reactivity with a polypeptide that consists of the amino acid sequence of SEQ ID NO:37, and that has immunological reactivity with CAPRIN-1 polypeptide.
4. The method of claim 1 , wherein the cancer is breast cancer, brain tumor, leukemia, lymphoma, lung cancer, mastocytoma, renal cancer, uterine cervix cancer, bladder cancer, esophageal cancer, gastric cancer, or colorectal cancer.
5. The method of claim 1 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.
6. The method of claim 1 , wherein the antibody is a human antibody, humanized antibody, chimeric antibody, single chain antibody, or bispecific antibody.
7. The method of claim 2 , wherein the cancer is breast cancer, brain tumor, leukemia, lymphoma, lung cancer, mastocytoma, renal cancer, uterine cervix cancer, bladder cancer, esophageal cancer, gastric cancer, or colorectal cancer.
8. The method of claim 2 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.
9. The method of claim 2 , wherein the antibody is a human antibody, humanized antibody, chimeric antibody, single chain antibody, or bispecific antibody.
10. The method of claim 2 , wherein the antibody has a cytotoxic activity against a cancer cell expressing a CAPRIN-1 protein.
11. The method of claim 1 , wherein the antibody or the fragment thereof comprises a heavy chain variable region comprising the CDRH1, CDRH2 and CDRH3 amino acid sequences of SEQ ID NOS: 40, 41, and 42 respectively and a light chain variable region comprising the CDRL1, CDRL2 and CDRL3 amino acid sequences of SEQ ID NOS: 44, 45, and 46 respectively, and has immunological reactivity with a CAPRIN-1 protein.
12. The method of claim 1 , wherein the antibody or the fragment thereof comprises a heavy chain variable region comprising the CDRH1, CDRH2 and CDRH3 amino acid sequences of SEQ ID NOS: 40, 41, and 42 respectively and a light chain variable region comprising the CDRL1, CDRL2 and CDRL3 amino acid sequences of SEQ ID NOS: 48, 49, and 50 respectively and has immunological reactivity with a CAPRIN-1 protein.
13. The method of claim 1 , wherein the antibody or the fragment thereof comprises a heavy chain variable region comprising the CDRH1, CDRH2 and CDRH3 amino acid sequences of SEQ ID NOS: 60, 61, and 62 respectively and a light chain variable region comprising the CDRL1, CDRL2 and CDRL3 amino acid sequences of SEQ ID NOS: 64, 65, and 66 respectively, and has immunological reactivity with a CAPRIN-1 protein.
14. The method of claim 11 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 43 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 47.
15. The method of claim 12 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 43 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 51.
16. The method of claim 13 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 63 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 67.
17. The method of claim 2 , wherein the antibody or the fragment thereof comprises a heavy chain variable region comprising the CDRH1, CDRH2 and CDRH3 amino acid sequences of SEQ ID NOS: 40, 41, and 42 respectively and a light chain variable region comprising the CDRL1, CDRL2 and CDRL3 amino acid sequences of SEQ ID NOS: 44, 45, and 46 respectively, and has immunological reactivity with a CAPRIN-1 protein.
18. The method of claim 2 , wherein the antibody or the fragment thereof comprises a heavy chain variable region comprising the CDRH1, CDRH2 and CDRH3 amino acid sequences of SEQ ID NOS: 40, 41, and 42 respectively and a light chain variable region comprising the CDRL1, CDRL2 and CDRL3 amino acid sequences of SEQ ID NOS: 48, 49, and 50 respectively and has immunological reactivity with a CAPRIN-1 protein.
19. The method of claim 2 , wherein the antibody or the fragment thereof comprises a heavy chain variable region comprising the CDRH1, CDRH2 and CDRH3 amino acid sequences of SEQ ID NOS: 60, 61, and 62 respectively and a light chain variable region comprising the CDRL1, CDRL2 and CDRL3 amino acid sequences of SEQ ID NOS: 64, 65, and 66 respectively, and has immunological reactivity with a CAPRIN-1 protein.
20. The method of claim 17 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 43 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 47.
21. The method of claim 18 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 43 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 51.
22. The method of claim 19 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 63 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 67.